SYNTARA LIMITED

Market Cap $41.29M Add to my watchlist

Syntara Limited is an Australia-based clinical-stage drug development company. The... Syntara Limited is an Australia-based clinical-stage drug development company. The Company is targeting extracellular matrix dysfunction with its amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The Company’s lead candidate SNT-5505 is for the bone marrow cancer myelofibrosis which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The Company is also advancing both oral and topical pan-LOX inhibitors in scar prevention and scar modification programs. Its product candidate, SNT-4728, is an inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis and cardiac fibrosis.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Latest Threads

	Tag	Subject

See All Discussions

(20min delay)
Last 5.4¢		Change 0.004(8.00%)		Mkt cap ! $41.29M

Open	High	Low	Value	Volume
5.2¢	5.5¢	5.2¢	$392.4K	7.362M

Buyers (Bids)

No.	Vol.	Price($)
4	183569	5.3¢

Sellers (Offers)

Price($)	Vol.	No.
5.5¢	134305	2

View Market Depth

No.	Vol.	Price($)
3	106747	0.032
2	179811	0.031
9	1434343	0.030
5	877931	0.029
3	1780000	0.028

Price($)	Vol.	No.
0.033	228097	1
0.034	661268	3
0.035	316000	2
0.036	371477	3
0.039	400000	1

Last trade - 12.16pm 29/11/2024 (20 minute delay)


Last 5.5¢		Change 0.004 ( 11.1 %)
Open	High	Low	Volume
5.3¢	5.5¢	5.2¢	876289
Last updated 12.33pm 29/11/2024 ?

SNT (ASX) Chart